Neurosense Therapeutics Ltd Stock Price, News & Analysis

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has announced its participation in the BIO-Europe Partnering Conference taking place from October 24-26, 2022, in Lepzing, Germany. The company's VP of Business Development, Nedira Salzman Frenkel, will engage with potential partners in the CNS space to explore collaboration opportunities. Concurrently, Dr. Niva Russek Blum, VP Discovery & IP Generator, will assess assets from various institutions focusing on neurological conditions. NeuroSense is dedicated to developing therapies for severe neurodegenerative diseases, such as ALS and Alzheimer's.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) provided a Q3 update, highlighting advancements in its Phase IIb study for PrimeC, a drug designed for ALS. The company achieved enrollment milestones with over one-third of patients enrolled and aims for completion by late 2022. They also established collaborations to enhance ALS diagnostics and presented significant findings at key scientific conferences. With over $9 million in cash, NeuroSense is positioned to continue its clinical development. CEO Alon Ben-Noon acknowledged ALS community advancements and expressed gratitude to stakeholders.

NeuroSense Therapeutics (NASDAQ: NRSN) is set to participate in the Nasdaq Opening Bell Ceremony on October 13, 2022. CEO Alon Ben Noon will lead the event, celebrating the company's achievements since going public. NeuroSense will also host The ALS Combination Therapy Summit, discussing critical ALS topics and featuring prominent thought leaders. The company’s Phase IIb PARADIGM trial for its lead drug candidate, PrimeC, is currently enrolling patients, with top-line data expected mid-2023. The ALS disease burden is significant, with over 5,000 new cases annually in the U.S.

NeuroSense Therapeutics (NASDAQ: NRSN) announced participation in the Cantor Fitzgerald Neurology and Psychiatry Conference on October 6-7, 2022, in San Francisco. CEO Alon Ben-Noon will join a panel on ALS, while Prof. Jeremy Shefner will be a keynote speaker. The company's lead drug, PrimeC, is in a Phase IIb trial aimed at treating ALS, with topline data expected in mid-2023. PrimeC has already demonstrated safety and efficacy in previous trials, and has received Orphan Drug Designation from the FDA and EMA.

NeuroSense Therapeutics (NRSN) announced positive results from a multi-dose pharmacokinetic (PK) study of its lead drug candidate PrimeC, targeting amyotrophic lateral sclerosis (ALS). The study demonstrated PrimeC's extended release properties and favorable safety profile, supporting its ongoing Phase IIb PARADIGM trial. PrimeC, a combination of celecoxib and ciprofloxacin, has shown effective simultaneous release and bioavailability, reinforcing its dosing regimen. The company anticipates pivotal Phase III trial design to align with FDA requirements based on these findings.

NeuroSense Therapeutics (Nasdaq: NRSN) announced its participation in two conferences focused on amyotrophic lateral sclerosis (ALS). Presentations will cover the efficacy of PrimeC, its lead drug candidate, in the Phase IIb PARADIGM trial, with primary endpoints including ALS biomarkers. The TRICALS Consortium Masterclass in the Netherlands (September 28-30) and ALS ONE's 5th Annual Symposium (October 6-7, 11) will feature updates from the company's experts. Topline results from the trial are expected in H1 2023.

NeuroSense Therapeutics announced positive results from its GLP toxicology study for PrimeC, a combination therapy for ALS. The study confirmed PrimeC's safety at doses over four times the maximal clinical dose, supporting the current Phase IIb PARADIGM trial design. This follows encouraging outcomes from a prior Phase IIa study. The PARADIGM trial aims to assess the efficacy and safety of PrimeC in ALS patients, with topline data expected in H1 2023. This milestone enhances the likelihood of favorable clinical outcomes and supports the drug's development strategy.

NeuroSense Therapeutics announced the peer-reviewed publication of Phase IIa data for its lead drug PrimeC, a combination of ciprofloxacin and celecoxib, targeting ALS. The study demonstrated safety in 15 participants and statistically significant changes in key biomarkers associated with ALS, such as TDP-43 and LC3. Based on promising outcomes, NeuroSense has initiated a Phase IIb clinical trial called PARADIGM. This trial aims to further explore PrimeC's efficacy in ALS treatment by evaluating biomarkers and quality of life improvements.

NeuroSense Therapeutics Ltd. (NRSN) reported its financial results for Q2 2022, highlighting the start of its Phase IIb ALS study and promising biomarker results. The company has over $10 million in cash, supporting its ongoing clinical programs. R&D expenses increased to $3.17 million, while administrative costs rose to $3.69 million, reflecting growth in salaries and professional services. Net loss for the first half of 2022 was $6.2 million, with a basic loss per share of $0.55. The completion of several studies and a key patent were also noted as significant advancements.